At the close of an inspection, FDA investigators may hand you a Form FDA 483 listing observations. It is easy to treat that piece of paper as the end of the inspection. It is the beginning of the part that matters.

A 483 is not a final finding. It lists conditions the investigator believes may violate the Federal Food, Drug, and Cosmetic Act. A warning letter is a different document, issued later, and FDA generally posts warning letters publicly. A common goal of a 483 response is to give FDA information it may weigh in deciding whether further action is needed. No response can ensure a particular outcome.

The clock. FDA generally asks for a written response within fifteen working days. Responses received inside that window are ordinarily considered before FDA decides whether to issue a warning letter. A response that arrives late may not be.

Elements of a well-organized response

• Answers each observation separately, in the order FDA listed them.
• Identifies a root cause rather than restating the observation and promising to do better.
• Separates corrections already completed from actions still planned, and gives realistic dates for the planned ones.
• Attaches evidence: revised procedures, training records, photographs, batch or monitoring records.
• Commits to follow-up updates and then actually sends them.

Common pitfalls

• A defensive or argumentative tone, or disputing an observation without documentation.
• Dates you cannot meet. A missed commitment in a written response can draw scrutiny from a later reviewer.
• Statements that conflict with your own records or with what the investigator observed.

Write it as though it will be read by someone other than FDA. Inspection records and responses can become public. Which rulebook you are measured against also depends on your status: outsourcing facilities under section 503B are held to current good manufacturing practice, while section 503A pharmacies are not subject to cGMP but remain subject to the statute’s insanitary-conditions provision.

Compliance gaps that go unaddressed can become the focus of enforcement matters. Four areas to review:

• Inventory and reconciliation. Required inventories (21 C.F.R. pt. 1304 (2026)) and routine reconciliation of what the records say against what is on the shelf. Unexplained variances can draw close attention.
• Theft and loss. A theft or significant loss must be reported to the DEA field division in writing within one business day of discovery, followed by a DEA Form 106 (21 C.F.R. § 1301.76(b) (2026)). It is a short window, and it runs from discovery, not from the point at which the cause is understood. Waiting to learn how big the problem is does not stop the clock.
• Corresponding responsibility. A prescription is valid only if issued for a legitimate medical purpose, and the pharmacist who fills it shares responsibility for that (21 C.F.R. § 1306.04(a) (2026)). Red flags that are noticed but not documented or resolved can lead to enforcement concerns.
• Ordering and handling. Schedule II orders require a DEA Form 222 or its electronic equivalent (21 C.F.R. pt. 1305 (2026)), and what was ordered should match what was received. Controlled substances should be stored securely, with access limited to those who need it (21 C.F.R. §§ 1301.71, 1301.75 (2026)).

If you receive an Order to Show Cause, the deadline to request a hearing is short (generally thirty days from receipt under 21 C.F.R. § 1301.43 (2026)). Do not let it sit in an inbox. In the most serious cases, DEA can move to suspend a registration immediately, which makes the earliest hours a legal matter and not an administrative one.

Opening a notice from the board of pharmacy gets anyone's attention, and what you do next matters. A board matter usually begins with a complaint, an inspection finding, or a referral from another agency. What happens next varies by state, but in many states the process follows a similar shape: investigation, a request for a written response, possibly an informal conference, and, if the matter does not resolve, a formal hearing.

The first written response often becomes the record. It can be read by an investigator, summarized for the board, and referred back to later. Calendar the deadline the day the notice arrives and request an extension in writing, early, if you need one.

Do not contact the complainant. It feels like good-faith problem solving. It can look like interference.

Resolution has ripple effects. A consent agreement in one state can trigger reporting obligations to other states’ boards, payor credentialing reviews, and data bank reports. For pharmacies and pharmacists licensed in multiple states, the question is often not only what this board will do. It is also what the order will mean in other jurisdictions.

Preserve relevant records. Once you know a matter is pending, stop routine deletion of records, emails, and logs that relate to it.